Prevention for LongevityInstitutionIntelligenceStandardWorkAboutDiscuss an opportunity

Public Proof Ledger · CLM-0015

ARPA-H awarded Linnaeus Therapeutics up to $21.9 million to test a GPER agonist for aging outcomes.

Sourced factCurrentPrimary/authoritativev1.1

Provenance

First verified
2026-02-24
Revision state
Version 1.1 records the September 3, 2026 re-verification and clarifies that the award funds an investigational test rather than establishing an aging or healthspan benefit.
Last verified
2026-09-03
Status
Program award · investigational testing · aging/healthspan benefit not established
Freshness
Current
Version
1.1
Fingerprint
d74cf69e1862939b
Change sensitivity
Medium

Evidence limits

The award says the team will test whether the compound improves aging outcomes; neither the award nor prior characterization establishes an aging or healthspan benefit.

For this decision

Researchers · Innovators · Funders/investors · Policymakers

Primary source

https://arpa-h.gov/explore-funding/awards/4196

Related signals